Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux J P
Antenne de l'Institut Francais de Recherche Scientifique pour le Developpement en Cooperation (ORSTOM) aupres du Centre Pasteur du Cameroun, Yaounde, Cameroon.
Am J Trop Med Hyg. 1998 Apr;58(4):461-9. doi: 10.4269/ajtmh.1998.58.461.
Over the past nine years, more than 12 million people exposed to Onchocerca volvulus infection have received at least one dose of ivermectin, almost all without serious adverse reactions. Since 1991, however, several cases with neurologic manifestations, including coma, have been reported after ivermectin treatment of persons infected with O. volvulus who also had concomitant Loa loa infection with very high microfilaremia (> 50,000 microfilariae/ml of blood). In 1995, four criteria were established to define probable cases of Loa encephalopathy temporally related to treatment with ivermectin (PLERI). The present paper describes three PLERI cases recorded in Cameroon and compares them with two others reported previously. Disorders of consciousness began 3-4 days after treatment. The objective neurologic signs were variable. The conditions improved favorably in three patients who benefited from early hospitalization and good nursing; their disorders of consciousness lasted only 2-3 days; the results of clinical examination became normal after one month and electroencephalographic abnormalities disappeared after 5-7 months. Conversely, late diagnosis and delay in proper management in two others probably led to worsening of the condition and to fatal outcome related to the usual complications of coma. In addition to these cases, patients w with high Loa microfilaremia also developed milder neurologic manifestations causing functional impairment lasting for at least one week after treatment. Before launching mass ivermectin distribution programs to control onchocerciasis in central Africa, communities in which the intensity of concomitant L. loa microfilaremia is high need to be identified, and specific educational measures and monitoring strategies should be developed and applied before they are treated.
在过去九年里,超过1200万感染盘尾丝虫的人接受了至少一剂伊维菌素治疗,几乎所有人都未出现严重不良反应。然而,自1991年以来,已有数例在接受伊维菌素治疗感染盘尾丝虫且同时感染罗阿丝虫且微丝蚴血症水平极高(>50,000条微丝蚴/毫升血液)的患者后出现包括昏迷在内的神经系统表现的病例报告。1995年,制定了四项标准来界定与伊维菌素治疗在时间上相关的可能的罗阿丝虫脑病病例(PLERI)。本文描述了在喀麦隆记录的三例PLERI病例,并将其与先前报告的另外两例进行比较。意识障碍在治疗后3 - 4天开始出现。客观的神经系统体征各不相同。三名患者因早期住院和良好护理而病情好转;他们的意识障碍仅持续2 - 3天;临床检查结果在一个月后恢复正常,脑电图异常在5 - 7个月后消失。相反,另外两名患者诊断延迟且未得到妥善处理,可能导致病情恶化,并因昏迷的常见并发症而死亡。除了这些病例外,罗阿丝虫微丝蚴血症水平高的患者在治疗后还出现了较轻的神经系统表现,导致功能障碍持续至少一周。在中部非洲开展大规模伊维菌素分发计划以控制盘尾丝虫病之前,需要确定同时感染罗阿丝虫微丝蚴血症程度高的社区,并在对其进行治疗之前制定并应用具体的教育措施和监测策略。